Moderator: Gwendolyn Sowa, MD, PhD
The field of biologic therapies continues to rapidly expand as new technologies become available. As we proceed with cautious optimism into this new realm of health care, the question of how quickly to translate a new biologic tool into clinical care becomes of paramount concern. Early translation can result in unanticipated side effects and complications, while requirement of additional preclinical evidence can prevent patient access to helpful therapies and curtail innovation. This debate will focus on the risks and benefits of rapid clinical translation and the threshold for initiating clinical trials.
Agenda
Introduction/Welcome
Gwendolyn Sowa, MD, PhD
Pro: Early Translation of Biologics into Human Clinical Studies
Wellington Hsu, MD; Jason Savage, MD
Con: Delaying Transition of Biologics to Collect Additional Basic Science Data
W. Mark Erwin, DC, PhD; James Kang, MD
Q&A/Discussion